Is Restylane Contour FDA approved for temples?

Yes, the FDA recently approved Restylane Contour specifically for improvement of temple hollowing, making it the first HA filler with a cleared indication in the temple region. This removes the off-label status and gives practices a regulatory-backed option for this common treatment area.

Can you use Restylane for temple volume loss?

Yes, Restylane Contour is now FDA-cleared for temple hollowing, which is a recognized marker of aging and a common injection site. This approval allows practices to offer temple treatment as a distinct, billable service area within their Restylane menu.

What new indications has Galderma added to Restylane?

Galderma has expanded Restylane's indication portfolio to include temple hollowing, building on existing approvals in the midface and lips. This reflects an industry trend of manufacturers seeking to differentiate their filler platforms by adding new anatomical zones beyond traditional treatment areas.

How does temple filler approval affect medspa revenue?

Temple approval adds a distinct, billable treatment area to your Restylane offerings and typically increases syringe consumption in comprehensive facial rejuvenation plans. It also strengthens patient education, since you can now cite FDA approval in consultations rather than discussing off-label use.

Will other filler brands get temple approvals?

Yes, industry experts expect similar temple and other anatomical approvals from competitors like AbbVie and Evolus as manufacturers expand indications to differentiate and defend market share. This mirrors the recent trend of neck approvals like Skinvive's, signaling a broader shift toward multi-zone filler portfolios.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

FDA Approves Restylane Contour for Temple Hollowing — Galderma Expands Filler Indication Portfolio

Galderma gains clearance for HA filler in temple region, adding a new anatomical indication to its Restylane platform.

By Evan at Inside MedSpa · Jul 3, 2026

1-YEAR MOVE

ABBV ▲11.6% EOLS ▼15.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%
EOLS	Evolus	−15.6%

The FDA has approved Restylane Contour for improvement of temple hollowing, expanding Galderma's indication portfolio beyond the midface and lips. Temple volume loss is a recognized marker of aging and a common off-label injection site; this approval gives practices a cleared product and removes regulatory ambiguity around the indication.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/restylane-contour-fda-approval-temple-hollowing/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

FDA Approves Restylane Contour for Temple Hollowing — Galderma Expands Filler Indication Portfolio

Share

Discussion

Leave a comment

By the time it's news, it's too late.